18-LUN-106-BMS (CA209816) Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC

Grants and Contracts Details

StatusActive
Effective start/end date8/16/188/24/23

Funding

  • Bristol Myers Squibb Company: $118,314.00